[Hemophilia News Today] Atomwise, a company that specializes in using artificial intelligence (AI) to develop small molecule medicines, will partner with GC Pharma to discover new ways of treating people with hemophilia.
[Korea Biomedical Review] GC said that it has partnered with Atomwise, a U.S. artificial intelligence-based drug development firm, to discover a new treatment candidate for hemophilia.
[BioSpace] Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to […]
[Cheddar] Abraham Heifets, Co-founder & CEO of Atomwise joins Cheddar to discuss the company’s recent funding round and it’s coronavirus-related projects.
[Nanalyze] Just a few weeks ago, Atomwise closed a $123 million Series B bringing their total funding so far to just over $174 million. The recent financing round includes new backing from two top-10 global insurance companies. Other notable investors include names like Monsanto, Tencent, Baidu Ventures, Khosla Ventures, Draper Associates, and OS Fund. The fresh […]